• Explore /
  • Poster
  • / Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.

Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.

Abstract Poster

Authors

Akihiro Ohba

Akihiro Ohba

National Cancer Center Hospital, Tokyo, Japan

Akihiro Ohba , Chigusa Morizane , Makoto Ueno , Satoshi Kobayashi , Yasuyuki Kawamoto , Yoshito Komatsu , Masafumi Ikeda , Mitsuhito Sasaki , Naohiro Okano , Junji Furuse , Nobuyoshi Hiraoka , Hiroshi Yoshida , Aya Kuchiba , Gakuto Ogawa , Kenichi Nakamura , Naoko Matsui , Yoshiaki Nakamura , Wataru Okamoto , Takayuki Yoshino , Takuji Okusaka

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

JMA-IIA00423

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS4654)

DOI

10.1200/JCO.2020.38.15_suppl.TPS4654

Abstract #

TPS4654

Poster Bd #

262

Abstract Disclosures

Similar Posters

First Author: Choong-kun Lee

First Author: Choong-kun Lee

First Author: Damon R. Reed

First Author: Ian E. Krop